 | |
| Clinical data | |
|---|---|
| Other names | UCB-0022; UCB0022 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H27Cl2N3O3 |
| Molar mass | 476.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Glovadalen (developmental code nameUCB-0022) is adopamineD1 receptorpositive allosteric modulator which is under development for the treatment ofParkinson's disease.[1][2][3][4][5][6] It has been found to potentiate the capacity of dopamine to activate the D1 receptor by 10-foldin vitro with no actions on otherdopamine receptors.[5][6] As of May 2024, glovadalen is inphase 2clinical trials for this indication.[1][2][5] The drug is under development byUCB Biopharma.[1][4][5] It is described as anorally active,centrally penetrantsmall molecule.[1][5][6]
Our analysis of dopaminergic therapies shows a continued emphasis on DA agonists and levodopa reformulation. These include Cerevel's tavapadon, a D1/D5 receptor partial agonist and UCB0022, a positive allosteric modulator of the D1 receptor, as well as approaches to sub-cutaneously deliver levodopa/carbidopa such as Abbvie's ABBV-951 and Neuroderm's ND0612.
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information. |